Neuroprotection

Vanqua Bio to Present Pre-Clinical Data on VQ-101, a Novel GCase Activator For The Treatment of GBA-Parkinson’s Disease

Retrieved on: 
Tuesday, February 27, 2024

CHICAGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio today announced that the company will participate in the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, which will be held in Lisbon, Portugal and virtually from March 5-9.

Key Points: 
  • CHICAGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio today announced that the company will participate in the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, which will be held in Lisbon, Portugal and virtually from March 5-9.
  • “We created Vanqua Bio with the aim of developing innovative therapies capable of effectively slowing or halting the progression of neurodegenerative disorders, including GBA-PD, which is the largest genetically defined subset of Parkinson’s disease,” said Jim Sullivan, PhD, Co-founder and Chief Executive Officer of Vanqua Bio.
  • “We look forward to discussing the pre-clinical characterization of our clinical stage program, VQ-101, a brain-penetrant small molecule allosteric activator of GCase.
  • Furthermore, we look forward to sharing data on the development of a live cell GCase activity assay, which has enabled measurement of GCase activation in our preclinical systems and will be used to assess GCase activation in our Phase 1 trial.”
    Title: VQ-101, A Small Molecule Allosteric Activator of Glucocerebrosidase, Demonstrates Neuroprotection in Models of GBA-Parkinson’s Disease and Robust In-Vivo Target Engagement

Red light therapy for neuro/cognitive benefits

Retrieved on: 
Friday, February 23, 2024

There is a simple and practical way – red light therapy to improve your brain function.

Key Points: 
  • There is a simple and practical way – red light therapy to improve your brain function.
  • Red light therapy (RLT), also known as low-level laser therapy (LLLT) or photobiomodulation (PBM), involves exposure to specific wavelengths of visible red and near-infrared light (660-850 nm) to stimulate biological processes in the body.
  • Red light therapy increases mitochondria function to promote balance between free radicals and antioxidants in the body.
  • Studies have highlighted red light therapy has a potential neuroprotective and disease-modifying role in treating Alzheimer's and Parkinson's patients.

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

Retrieved on: 
Thursday, February 22, 2024

BOTHELL, Wash., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the year ended December 31, 2023, and reviewed recent pipeline and business updates.

Key Points: 
  • In December 2023, the Company announced encouraging results from the exploratory Phase 2 SHAPE clinical trial to evaluate fosgonimeton in patients with Parkinson's disease dementia and dementia with Lewy bodies.
  • In May 2023, Athira selected the 40 mg dose for further development and potential regulatory approval.
  • In January 2024, Athira completed enrollment of the LIFT-AD study, randomizing approximately 315 patients in the primary analysis population.
  • In December 2023, Athira announced encouraging results from the exploratory SHAPE Phase 2 clinical trial of fosgonimeton for the potential treatment of Parkinson's disease dementia and dementia with Lewy bodies.

Cepham Introduces Senolytics Inspired by Ayurveda and TCM for Sustainable Aging

Retrieved on: 
Tuesday, February 20, 2024

SOMERSET, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cepham , a leader in Ayurvedic nutraceuticals research and sustainable self-care solutions, has announced the expansion of its Sustainable Aging product line to include senolytics, aimed at redefining approaches to healthy aging.

Key Points: 
  • SOMERSET, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cepham , a leader in Ayurvedic nutraceuticals research and sustainable self-care solutions, has announced the expansion of its Sustainable Aging product line to include senolytics, aimed at redefining approaches to healthy aging.
  • “Cepham’s decision to include senolytics in its Sustainable Aging ingredient offerings reflects our company's commitment to delivering affordable, high-quality, evidence-based, and safe ingredients to customers,” says Christopher Lamb , vice president of commercial strategy at Cepham.
  • The expansion of senolytics in Cepham’s Sustainable Aging product line marks a pivotal moment in the evolution of longevity solutions.
  • For more information about Cepham, Inc. and its Sustainable Aging Product line, please visit https://cepham.com .

Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease

Retrieved on: 
Tuesday, February 6, 2024

The data was accepted as a late-breaker abstract and will be presented at the 20th Annual WORLDSymposium™ being held in San Diego this week.

Key Points: 
  • The data was accepted as a late-breaker abstract and will be presented at the 20th Annual WORLDSymposium™ being held in San Diego this week.
  • “We believe the data showing complete restoration of motor function in a therapeutic model are remarkable and further support the potential of GT-02287 to slow or stop the progression of Parkinson’s disease, a disease for which only symptomatic treatments are available to patients at this time,” said Matthias Alder, Gain Therapeutics’ Chief Executive Officer.
  • Further, animals in the most challenging treatment group – those that began treatment eight days following onset of the disease – showed motor improvement from day 14 to day 27, which suggests progressive reversal of neuronal deficit associated with continued treatment duration.
  • Further details of the study, including protocol and specific results can be found in the poster, which was presented today and can be accessed here .

Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update

Retrieved on: 
Wednesday, January 31, 2024

In 2023, we advanced GT-02287 through preclinical development and initiated the company’s first clinical trial in September 2023 on time and on plan.

Key Points: 
  • In 2023, we advanced GT-02287 through preclinical development and initiated the company’s first clinical trial in September 2023 on time and on plan.
  • The dose escalation of the SAD phase is underway, and the MAD phase of the study is expected to begin in Q1 2024.
  • In 2023, we made several data presentations of results of our GBA1 program in preclinical models of Parkinson’s disease and Alzheimer’s disease.
  • Xavi is leaving the world of academia as a professor at the University of Barcelona and his part-time engagement with Gain to join a major pharmaceutical company.

Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada

Retrieved on: 
Tuesday, January 16, 2024

TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced an update on the Company’s project evaluating Bucillamine as a potential treatment for nerve agent exposure with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence.

Key Points: 
  • TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced an update on the Company’s project evaluating Bucillamine as a potential treatment for nerve agent exposure with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence.
  • The Company and the DRDC have finalized the research protocol and expect the project to be completed by the end of Q2-2024.
  • DRDC is investigating pharmacological compounds that can mitigate nerve agent induced brain injury.
  • Bucillamine and NAC will be evaluated to determine the effect on GABA(A) receptor endocytosis and the effect on diazepam effectiveness in terminating seizures.

Aruna Bio Announces FDA Clearance of IND for Lead Program AB126, Enabling the First Exosome to Enter in Human Clinical Trials for a Neurological Indication

Retrieved on: 
Tuesday, January 16, 2024

BOSTON and ATHENS, Ga., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a pioneer in the development of neural exosome-based therapeutics for the treatment of neurodegenerative diseases, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of lead program, AB126. This decision paves the way for the Phase 1b/2a clinical trial in acute ischemic stroke, which is expected to initiate in the first half of 2024. AB126 is an unmodified neural-derived exosome with an innate ability to traverse the blood brain barrier and shows evidence of anti-inflammatory and neuroprotective properties.

Key Points: 
  • This decision paves the way for the Phase 1b/2a clinical trial in acute ischemic stroke, which is expected to initiate in the first half of 2024.
  • AB126 is an unmodified neural-derived exosome with an innate ability to traverse the blood brain barrier and shows evidence of anti-inflammatory and neuroprotective properties.
  • “We are thrilled with this validation from the FDA, which not only positions AB126 as the first exosome to enter human clinical trials for a neurological indication, but underscores the therapeutic feasibility of our platform,” said Steven Stice, Ph.D., Co-Founder and Chief Scientific Officer of Aruna.
  • “Further, maintaining cells under controlled conditions is a key aspect of exosome manufacturing and we look forward to leveraging our in-house GMP manufacturing expertise to support clinical advancement.

Combination Therapy and Precision Medicine Spotlighted as the Gold Standard for the Next Generation of Alzheimer's Treatments in the Journal of Prevention of Alzheimer's Disease (JPAD)

Retrieved on: 
Tuesday, January 16, 2024

NEW YORK, Jan. 16, 2024 /PRNewswire/ -- The Journal of Prevention of Alzheimer's Disease (JPAD) with the support of the Alzheimer's Drug Discovery Foundation (ADDF) recently published a comprehensive issue, "The Biology of Aging: Leading The Next Generation of Alzheimer's Drug Development With a Geroscience Focus," which supports the consensus that combination therapy and precision medicine are the future of Alzheimer's treatment. This landmark publication arrives at a critical time in the Alzheimer's research field following significant drug breakthroughs of anti-amyloid therapies and the emergence of the biology of aging as the leading approach for drug development. This issue emphasizes the need to advance new therapies that target the underlying biology of the disease while also offering a roadmap for the next generation of Alzheimer's therapies.

Key Points: 
  • This issue emphasizes the need to advance new therapies that target the underlying biology of the disease while also offering a roadmap for the next generation of Alzheimer's therapies.
  • Each of these novel targets introduces a new and much-needed multi-pronged approach for developing Alzheimer's treatments, which can complement anti-amyloid drugs on the market.
  • The development of future therapies will enhance our growing understanding of the disease and how the various pathways interact to affect the disease state."
  • "This is a noteworthy achievement, as the publication will serve as the first extensive roadmap of non-amyloid pathways with the potential to address the complexity of Alzheimer's disease."

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024

Retrieved on: 
Tuesday, January 2, 2024

BETHESDA, Md., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a late-breaking abstract with new data of GT-02287 in preclinical models of Parkinson’s disease has been accepted for a platform presentation at the 20 th Annual WORLDSymposium™ being held February 4-9, 2024 in San Diego, CA.

Key Points: 
  • BETHESDA, Md., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a late-breaking abstract with new data of GT-02287 in preclinical models of Parkinson’s disease has been accepted for a platform presentation at the 20 th Annual WORLDSymposium™ being held February 4-9, 2024 in San Diego, CA.
  • Details of the platform presentation are as follows:
    Title: GT-02287, a clinical stage GCase enhancer, displays neuroprotection and restores motor function in preclinical models of Parkinson’s disease following delayed administration